|
Market Closed -
Nasdaq
16:00:00 2024-12-23 EST
|
5-day change | 1st Jan Change | ||
| 0.2531 USD | +4.20% |
|
-.--% | - |
| 09-18 | Neuphoria Therapeutics Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 07-23 | Scancell Holdings plc agreed to acquire Neuphoria Therapeutics Inc. for $35 million. | CI |
Projected Income Statement: BIONOMICSSADR
Annual
Quarterly
Halfyear
Annual
Quarterly
Halfyear
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.49 | 0.5996 | 3.513 | 23.79 | 1.652 | - | - |
| Change | - | -89.08% | 485.9% | 577.2% | -93.06% | - | - |
| EBITDA 1 | -20.8 | -30.87 | -26.17 | -1.717 | -22.21 | -26.31 | -30.74 |
| Change | - | -48.42% | 15.21% | 93.44% | -1,193.82% | -18.46% | -16.85% |
| EBIT 1 | -21.91 | -32.02 | -27.18 | -1.717 | -23.14 | -26.31 | -30.74 |
| Change | - | -46.18% | 15.13% | 93.68% | -1,248.15% | -13.68% | -16.85% |
| Interest Paid | -0.0442 | -0.0292 | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -21.95 | -32.05 | -23.67 | -1.274 | -19.12 | -24.88 | -29.45 |
| Change | - | -46.02% | 26.17% | 94.62% | -1,400.66% | -30.13% | -18.39% |
| Net income 1 | -21.76 | -31.85 | -23.53 | -0.562 | -18.92 | -24.59 | -29.17 |
| Change | - | -46.36% | 26.11% | 97.61% | -3,267.35% | -29.96% | -18.6% |
| Announcement Date | 8/25/22 | 9/29/23 | 11/8/24 | 9/29/25 | 9/18/26 | - | - |
1AUD in Million
Estimates
Forecast Balance Sheet: BIONOMICSSADR
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - |
| Announcement Date | 8/25/22 | 9/29/23 | 11/8/24 | 9/29/25 | 9/18/26 | - | - |
Estimates
Cash Flow Forecast: BIONOMICSSADR
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| CAPEX 1 | 0.001468 | 0.001544 | - | - | - | - |
| Change | - | 5.18% | - | - | - | - |
| Free Cash Flow (FCF) 1 | -2.86 | -11.89 | -7.178 | -7.925 | 0.4617 | -8.339 |
| Change | - | -315.64% | 39.62% | -10.42% | 105.83% | -1,906.09% |
| Announcement Date | 8/25/21 | 8/25/22 | 9/29/23 | 9/30/24 | 9/29/25 | 9/18/26 |
1USD in Million
Estimates
Forecast Financial Ratios: BIONOMICSSADR
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | -378.84% | -5,147.68% | -744.93% | -7.21% | -1,344.62% | - | - |
| EBIT Margin (%) | - | -399.05% | -5,340.62% | -773.59% | -7.21% | -1,401.08% | - | - |
| EBT Margin (%) | - | -399.85% | -5,345.5% | -673.59% | -5.35% | -1,157.51% | - | - |
| Net margin (%) | - | -396.36% | -5,311.01% | -669.82% | -2.36% | -1,145.66% | - | - |
| FCF margin (%) | - | - | -3,559.36% | - | - | - | - | - |
| FCF / Net Income (%) | - | - | 67.02% | - | - | - | - | - |
Profitability | ||||||||
| ROA | -14.48% | -18.4% | -32.11% | -39.58% | -1.84% | -19.65% | - | - |
| ROE | -28.86% | -41.64% | -70.72% | -78.44% | -2.03% | -61.7% | - | - |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | - | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| EPS 1 | - | - | - | - | -0.23 | -3.06 | -2.43 | -2.46 |
| Change | - | - | - | - | - | -1,230.43% | 20.59% | -1.23% |
| Nbr of stocks (in thousands) | - | - | - | - | 1,880 | 5,405 | 5,411 | 5,411 |
| Announcement Date | - | - | - | - | 9/29/25 | 9/18/26 | - | - |
1USD
Estimates
| 2027 * | 2028 * | |
|---|---|---|
| P/E | -1.43x | -1.41x |
| PBR | - | - |
| EV / Sales | - | - |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy

Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.470
Average target price
-
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NEUP Stock
- BNOX Stock
- Financials BIONOMICSSADR
Select your edition
All financial news and data tailored to specific country editions
















